Developing long-lasting buprenorphine treatments for opioid addiction
Long acting biodegradable buprenorphine depots
This study is testing a new way to deliver buprenorphine, a medication that helps people recover from opioid addiction, by creating a longer-lasting version that means you won't have to take it as often, and it's designed to be safe for the body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10908653 on NIH RePORTER |
What this research studies
This research focuses on creating a new biodegradable delivery system for buprenorphine, a medication used to help individuals overcome opioid addiction. The goal is to develop a longer-acting formulation that can improve patient adherence to treatment by reducing the frequency of dosing. The project will involve a pilot clinical trial to test the pharmacokinetics of this new formulation in healthy volunteers, aiming to ensure that it releases medication effectively over an extended period. By utilizing established biocompatible polymers, the research seeks to streamline the regulatory process for bringing this new treatment to patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are currently undergoing treatment for opioid use disorder or are at risk of opioid addiction.
Not a fit: Patients who are not struggling with opioid addiction or who are not interested in medication-assisted treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for individuals struggling with opioid addiction.
How similar studies have performed: Previous research has shown success with similar biodegradable drug delivery systems, indicating a promising approach for this treatment.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Otte, Andrew — Purdue University
- Study coordinator: Otte, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.